FDA Approves Relacorilant for Ovarian, Fallopian, and Peritoneal Cancer...
Published: Friday, 27 Mar 2026 by The Insight PartnersThe U.S. Food and Drug Administration approved relacorilant in combination with nab-paclitaxel, offering a new treatment option for adults with platinum-resistant epithelial ovarian, fallopian tube, o... Read the news




